OUR MISSION
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment.
The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
OFFERING
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
THE PSYCHEDELICS AS MEDICINE REPORT
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. PSYCH: The Psychedelics as Medicine Report provides unparalleled insights and intelligence from industry experts and market leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report examines:
- Essential insights into the nascent psychedelics market
- Deep dives into the most transformative compounds and companies
- Key regulations, transformative trends and commercial opportunities
V2 COMING AUGUST 2020...
HIGHLIGHTS
PSYCH: What are the next steps for investors?
PSYCH: What Lies Ahead? The Future of Therapy
PSYCH: Psychedelics for Substance Use
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS & INSIGHT
PSYCH Symposium
PSYCH Symposium at Prohibition Partners LIVE brought together world-class speakers, industry giants and pioneering investors, to discuss psychedelics and their potential to disrupt how we treat mental health. Read the highlights.
Interview: Eva Césarová
Eva Césarová is the media coordinator for psychedelic research at the National Institute of Mental Health in Czech Republic and a co-founding member of the Czech Psychedelic Society.
Interview: George Goldsmith
George Goldsmith is a co-founder and director of COMPASS – a non-profit medical research organisation dedicated to accelerating access to evidence-led innovation in mental health and wellbeing.
THE PSYCHEDELICS NEWSLETTER
Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.
